IL183401A - Use of ornithine and ornithine with at least one of phenylacetate and phenylbutyrate in the manufacture of products and compositions containing them for use in preventing or treating liver decompensation or hepatic encephalopathy - Google Patents

Use of ornithine and ornithine with at least one of phenylacetate and phenylbutyrate in the manufacture of products and compositions containing them for use in preventing or treating liver decompensation or hepatic encephalopathy

Info

Publication number
IL183401A
IL183401A IL183401A IL18340107A IL183401A IL 183401 A IL183401 A IL 183401A IL 183401 A IL183401 A IL 183401A IL 18340107 A IL18340107 A IL 18340107A IL 183401 A IL183401 A IL 183401A
Authority
IL
Israel
Prior art keywords
ornithine
liver
phenyl
manufacture
encephalopathy
Prior art date
Application number
IL183401A
Other languages
English (en)
Hebrew (he)
Other versions
IL183401A0 (en
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0426141A external-priority patent/GB0426141D0/en
Priority claimed from GB0426142A external-priority patent/GB0426142D0/en
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of IL183401A0 publication Critical patent/IL183401A0/en
Publication of IL183401A publication Critical patent/IL183401A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL183401A 2004-11-26 2007-05-24 Use of ornithine and ornithine with at least one of phenylacetate and phenylbutyrate in the manufacture of products and compositions containing them for use in preventing or treating liver decompensation or hepatic encephalopathy IL183401A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0426141A GB0426141D0 (en) 2004-11-26 2004-11-26 Treatment
GB0426142A GB0426142D0 (en) 2004-11-26 2004-11-26 Formulation
PCT/GB2005/004539 WO2006056794A1 (en) 2004-11-26 2005-11-28 Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy

Publications (2)

Publication Number Publication Date
IL183401A0 IL183401A0 (en) 2007-10-31
IL183401A true IL183401A (en) 2013-09-30

Family

ID=35559327

Family Applications (1)

Application Number Title Priority Date Filing Date
IL183401A IL183401A (en) 2004-11-26 2007-05-24 Use of ornithine and ornithine with at least one of phenylacetate and phenylbutyrate in the manufacture of products and compositions containing them for use in preventing or treating liver decompensation or hepatic encephalopathy

Country Status (22)

Country Link
US (3) US8389576B2 (enExample)
EP (3) EP2319581B1 (enExample)
JP (2) JP5116479B2 (enExample)
KR (1) KR101380446B1 (enExample)
CN (1) CN102512408B (enExample)
AT (1) ATE457187T1 (enExample)
AU (1) AU2005308622B2 (enExample)
CA (1) CA2589261C (enExample)
CY (3) CY1112259T1 (enExample)
DE (1) DE602005019319D1 (enExample)
DK (3) DK2153870T3 (enExample)
EA (2) EA018007B1 (enExample)
ES (3) ES2537974T3 (enExample)
IL (1) IL183401A (enExample)
MX (1) MX2007006171A (enExample)
NO (2) NO342198B1 (enExample)
NZ (1) NZ555870A (enExample)
PL (3) PL1824563T3 (enExample)
PT (3) PT2319581E (enExample)
SG (1) SG158073A1 (enExample)
SI (3) SI2153870T1 (enExample)
WO (1) WO2006056794A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5116479B2 (ja) 2004-11-26 2013-01-09 ユーシーエル ビジネス ピーエルシー オルニチンならびにフェニルアセテートまたはフェニルブチレートを含む、肝性脳症を治療するための組成物
PL3133396T3 (pl) * 2008-04-29 2019-03-29 Horizon Therapeutics, Llc Sposób leczenia z zastosowaniem leków wychwytujących amoniak
CA2735234A1 (en) * 2008-08-29 2010-03-04 Ucyclyd Pharma, Inc. Dosing and monitoring patients on nitrogen-scavenging drugs
MX364102B (es) 2008-10-02 2019-04-12 Salix Pharmaceuticals Ltd Medicamentos para usarse en el tratamiento de la encefalopatía hepática.
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
ES2928586T3 (es) * 2009-04-03 2022-11-21 Ocera Therapeutics Inc Fenilacetato de L-ornitina y métodos para elaborar el mismo
KR101715008B1 (ko) 2009-06-08 2017-03-22 유씨엘 비즈니스 피엘씨 Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복
EP2397458A1 (en) * 2010-06-21 2011-12-21 Lunamed AG Organic salts and co-crystals of phenylbutyric acid
JP6087284B2 (ja) * 2010-10-06 2017-03-01 オセラ セラピューティクス， インコーポレイテッド Ｌ−オルニチンフェニルアセテートを製造するための方法
BR112014007357B1 (pt) 2011-09-30 2022-12-06 Immedica Pharma Ab Método para determinar o ajuste da dosagem de um fármaco de varredura de nitrogênio
EP3222275B1 (en) 2012-04-20 2020-06-24 Immedica Pharma AB Methods of therapeutic monitoring of phenylacetic acid prodrugs
ES2654774T3 (es) 2012-11-21 2018-02-15 Horizon Therapeutics, Llc Métodos para administrar y evaluar fármacos de recuperación de nitrógeno para el tratamiento de encefalopatía hepática
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
WO2015048818A1 (en) * 2013-09-30 2015-04-02 Hyperion Therapeutics, Inc. Diagnosing, grading, monitoring, and treating hepatic encephalopathy
US20160339040A1 (en) 2014-01-29 2016-11-24 Umecrine Cognition Ab Steroid compound for use in the treatment of hepatic encephalopathy
DK3223829T3 (da) * 2014-11-24 2020-02-10 Ucl Business Ltd Behandling af sygdomme associeret med hepatisk stellat-celleaktivering under anvendelse af ammoniak-sænkende terapier
TWI748936B (zh) 2015-01-12 2021-12-11 瑞典商優鎂奎認知Ａｂ公司 新穎化合物
RU2755904C2 (ru) * 2015-04-20 2021-09-22 Осера Терапьютикс, Инк. Составы l-орнитин фенилацетата
HK1249434A1 (zh) * 2015-08-18 2018-11-02 Ocera Therapeutics, Inc. 使用与苯乙酸盐和苯丁酸盐中的至少一种组合的l-鸟氨酸治疗和预防肌肉损失
WO2017053613A1 (en) 2015-09-25 2017-03-30 Ocera Therapeutics, Inc. Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
MX389926B (es) * 2015-11-13 2025-03-20 Ocera Therapeutics Inc Formulaciones de fenilacetato de l-ornitina
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
WO2017090007A1 (en) * 2015-11-29 2017-06-01 Rao M Surya Compositions and methods for the treatment of urea cycle disorders and hepatic diseases
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CA3063134A1 (en) 2017-05-11 2018-11-15 Ocera Therapeutics, Inc. Processes of making l-ornithine phenylacetate
WO2018225167A1 (ja) 2017-06-07 2018-12-13 花王株式会社 アンモニア代謝促進剤
WO2018225482A1 (ja) 2017-06-07 2018-12-13 花王株式会社 アンモニア代謝促進剤
BR112020002419A2 (pt) 2017-08-14 2020-07-28 Axcella Health Inc. aminoácido para o tratamento de doença do fígado
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
WO2019246225A1 (en) 2018-06-20 2019-12-26 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
JP7197340B2 (ja) * 2018-12-06 2022-12-27 花王株式会社 認知機能改善剤
MX2021013526A (es) 2019-05-09 2021-12-10 Ocera Therapeutics Inc Metodos de evaluacion y tratamiento de encefalopatia hepatica.
CN113713817B (zh) * 2020-05-26 2023-06-27 中国科学院大连化学物理研究所 一种采用镍基催化剂催化丙醛加氢制正丙醇的方法
US20230416292A1 (en) * 2020-12-01 2023-12-28 Wellstat Therapeutics Corporation 5'-O-Phenylacetyluridine and therapeutic use
WO2024261477A1 (en) 2023-06-20 2024-12-26 Yaqrit Limited Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate
WO2025137400A1 (en) * 2023-12-20 2025-06-26 Cedars-Sinai Medical Center Use of tenapanor for the treatment or prevention of hepatic encephalopathy

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE380814A (enExample) * 1930-06-26
US1980422A (en) * 1931-09-30 1934-11-13 Mesick John Plotting board
US2271378A (en) * 1939-08-30 1942-01-27 Du Pont Pest control
US2273780A (en) * 1939-12-30 1942-02-17 Du Pont Wax acryalte ester blends
US2261002A (en) * 1941-06-17 1941-10-28 Du Pont Organic nitrogen compounds
US2388614A (en) * 1942-05-05 1945-11-06 Du Pont Disinfectant compositions
US2375853A (en) * 1942-10-07 1945-05-15 Du Pont Diamine derivatives
US2454547A (en) * 1946-10-15 1948-11-23 Rohm & Haas Polymeric quaternary ammonium salts
US2723248A (en) * 1954-10-01 1955-11-08 Gen Aniline & Film Corp Film-forming compositions
US2961347A (en) * 1957-11-13 1960-11-22 Hercules Powder Co Ltd Process for preventing shrinkage and felting of wool
GB965637A (en) 1962-04-23 1964-08-06 Tanabe Seiyaku Co L-ornithine l-aspartate
US3227615A (en) * 1962-05-29 1966-01-04 Hercules Powder Co Ltd Process and composition for the permanent waving of hair
US3206462A (en) * 1962-10-31 1965-09-14 Dow Chemical Co Quaternary poly(oxyalkylene)alkylbis(diethylenetriamine) compounds
NL302572A (enExample) 1962-12-27
GB1067742A (en) 1963-09-16 1967-05-03 Kyowa Hakko Kogyo Kk Process for the preparation of l-ornithine l-aspartate
US3256154A (en) * 1963-10-18 1966-06-14 Gillette Co Hair waving composition and method
FR1517743A (fr) * 1966-08-03 1968-03-22 Oreal Nouveaux copolymères et compositions cosmétiques contenant ces copolymères
US3472840A (en) * 1965-09-14 1969-10-14 Union Carbide Corp Quaternary nitrogen-containing cellulose ethers
US3810977A (en) * 1967-03-23 1974-05-14 Nat Starch Chem Corp Hair fixing composition and process containing a solid terpolymer
CH491153A (de) * 1967-09-28 1970-05-31 Sandoz Ag Verfahren zur Herstellung von neuen kationaktiven, wasserlöslichen Polyamiden
US3836537A (en) * 1970-10-07 1974-09-17 Minnesota Mining & Mfg Zwitterionic polymer hairsetting compositions and method of using same
ZA716628B (en) 1970-10-15 1972-06-28 Richardson Merrell Spa Composition and method for treatment of hepatic disease and mental fatigue
FR2113774A1 (en) 1970-11-13 1972-06-30 Roques Ets Prepn of l-ornithine salts with org acids - using silver oxides
US4013787A (en) * 1971-11-29 1977-03-22 Societe Anonyme Dite: L'oreal Piperazine based polymer and hair treating composition containing the same
LU64371A1 (enExample) * 1971-11-29 1973-06-21
LU65552A1 (enExample) * 1972-06-20 1973-12-27
CA981746A (en) * 1973-09-24 1976-01-13 Alfred M. Hase Battery charging circuit
US4277581A (en) * 1973-11-30 1981-07-07 L'oreal Polyamino-polyamide crosslinked with crosslinking agent
US4172887A (en) * 1973-11-30 1979-10-30 L'oreal Hair conditioning compositions containing crosslinked polyaminopolyamides
US4189468A (en) * 1973-11-30 1980-02-19 L'oreal Crosslinked polyamino-polyamide in hair conditioning compositions
US4025627A (en) * 1973-12-18 1977-05-24 Millmaster Onyx Corporation Microbiocidal polymeric quaternary ammonium compounds
US3929990A (en) * 1973-12-18 1975-12-30 Millmaster Onyx Corp Microbiocidal polymeric quaternary ammonium compounds
US3874870A (en) * 1973-12-18 1975-04-01 Mill Master Onyx Corp Microbiocidal polymeric quarternary ammonium compounds
US4166894A (en) * 1974-01-25 1979-09-04 Calgon Corporation Functional ionene compositions and their use
DK659674A (enExample) * 1974-01-25 1975-09-29 Calgon Corp
LU69759A1 (enExample) * 1974-04-01 1976-03-17
LU69760A1 (enExample) * 1974-04-01 1976-03-17
US4100293A (en) 1974-04-15 1978-07-11 The Johns Hopkins University Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids
US5196189A (en) * 1974-05-16 1993-03-23 Societe Anonyme Dite: L'oreal Quaternized polymer for use as a cosmetic agent in cosmetic compositions for the hair and skin
US4422853A (en) * 1974-05-16 1983-12-27 L'oreal Hair dyeing compositions containing quaternized polymer
US4217914A (en) * 1974-05-16 1980-08-19 L'oreal Quaternized polymer for use as a cosmetic agent in cosmetic compositions for the hair and skin
US4948579A (en) * 1974-05-16 1990-08-14 Societe Anonyme Dite: L'oreal Quaternized polymer for use as a cosmetic agent in cosmetic compositions for the hair and skin
US4005193A (en) * 1974-08-07 1977-01-25 Millmaster Onyx Corporation Microbiocidal polymeric quaternary ammonium compounds
US3966904A (en) * 1974-10-03 1976-06-29 Millmaster Onyx Corporation Quaternary ammonium co-polymers for controlling the proliferation of bacteria
US4026945A (en) * 1974-10-03 1977-05-31 Millmaster Onyx Corporation Anti-microbial quaternary ammonium co-polymers
US4025617A (en) * 1974-10-03 1977-05-24 Millmaster Onyx Corporation Anti-microbial quaternary ammonium co-polymers
US4027020A (en) * 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US4001432A (en) * 1974-10-29 1977-01-04 Millmaster Onyx Corporation Method of inhibiting the growth of bacteria by the application thereto of capped polymers
US3950529A (en) 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
US4025653A (en) * 1975-04-07 1977-05-24 Millmaster Onyx Corporation Microbiocidal polymeric quaternary ammonium compounds
AT365448B (de) * 1975-07-04 1982-01-11 Oreal Kosmetische zubereitung
US4197865A (en) * 1975-07-04 1980-04-15 L'oreal Treating hair with quaternized polymers
DE2715297A1 (de) * 1976-04-06 1977-10-27 Oreal N-alkyl-acrylamid oder -methacrylamid- mischpolymerisate, verfahren zu deren herstellung und diese enthaltende kosmetische mittel
US4031307A (en) * 1976-05-03 1977-06-21 Celanese Corporation Cationic polygalactomannan compositions
GB1572837A (en) * 1976-05-06 1980-08-06 Berger Jenson & Nicholson Ltd Coating composition
US4128631A (en) * 1977-02-16 1978-12-05 General Mills Chemicals, Inc. Method of imparting lubricity to keratinous substrates and mucous membranes
LU78153A1 (fr) * 1977-09-20 1979-05-25 Oreal Compositions cosmetiques a base de polymeres polyammonium quaternaires et procede de preparation
US4131576A (en) * 1977-12-15 1978-12-26 National Starch And Chemical Corporation Process for the preparation of graft copolymers of a water soluble monomer and polysaccharide employing a two-phase reaction system
US4320146A (en) 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4228099A (en) 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4348202A (en) * 1978-06-15 1982-09-07 L'oreal Hair dye or bleach supports
US4970066A (en) * 1978-06-15 1990-11-13 L'oreal Hair dye or bleach supports of quaternized polymers
FR2439798A1 (fr) * 1978-10-27 1980-05-23 Oreal Nouveaux copolymeres utilisables en cosmetique, notamment dans des laques et lotions de mises en plis
US4352814A (en) 1979-04-18 1982-10-05 The Johns Hopkins University Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
LU83349A1 (fr) * 1981-05-08 1983-03-24 Oreal Composition sous forme de mousse aerosol a base de polymere cationique et de polymere anionique
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
LU84463A1 (fr) * 1982-11-10 1984-06-13 Oreal Polymeres polysiloxanes polyquaternaires
LU84708A1 (fr) * 1983-03-23 1984-11-14 Oreal Composition epaissie ou gelifiee de conditionnement des cheveux contenant au moins un polymere cationique,au moins un polymere anionique et au moins une gomme de xanthane
US4812307A (en) * 1983-07-06 1989-03-14 Chesebrough-Pond's Inc. Crosslinking of hair thiols using glutathione disulfide
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
EP0269107A3 (en) * 1986-11-28 1989-10-11 Kao Corporation Composition for hair treatment agent
US4749732A (en) * 1987-01-02 1988-06-07 Dow Corning Corporation Hair care composition containing modified aminoalkyl substituted polydiorganosiloxane
US5139981A (en) 1987-06-24 1992-08-18 Union Carbide Chemicals & Plastics Technology Corporation Process for preparing silver(I)-exchanged resins
US4795629A (en) * 1987-07-06 1989-01-03 Chesebrough-Pond's Inc. Crosslinking of hair thiols using cystamine
LU87310A1 (fr) * 1988-08-04 1990-03-13 Oreal N-(mercaptoalkyl)omega-hydroxyalkylamides et leur utilisation en tant qu'agents reducteurs,dans un procede de deformation permanente des cheveux
FR2654617B1 (fr) * 1989-11-20 1993-10-08 Oreal Composition cosmetique reductrice pour permanente contenant, en tant qu'agent reducteur, de l'aletheine ou l'un de ses sels, et son utilisation dans un procede de deformation permanente des cheveux.
US5591613A (en) 1990-07-02 1997-01-07 Degussa Aktiengesellschaft Method for the preparation of D-arginine and L-ornithine
DE4020980C1 (enExample) 1990-07-02 1991-09-26 Degussa Ag, 6000 Frankfurt, De
JP3127484B2 (ja) * 1991-02-28 2001-01-22 味の素株式会社 肝炎治療薬
FR2676441B1 (fr) * 1991-05-17 1994-10-28 Oreal Nouveaux alkylamino-mercaptoalkylamides ou l'un de leurs sels cosmetiquement acceptables, et leur utilisation en tant qu'agents reducteurs, dans un procede de deformation permanente des cheveux.
FR2677543B1 (fr) * 1991-06-13 1993-09-24 Oreal Composition cosmetique filtrante a base d'acide benzene 1,4-di(3-methylidene-10-camphosulfonique) et de nanopigments d'oxydes metalliques.
US5767086A (en) * 1992-04-03 1998-06-16 Terrapin Technologies, Inc. Bone marrow stimulation by certain glutathione analogs
US5571783A (en) 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
JP3273578B2 (ja) 1993-09-21 2002-04-08 第一化学薬品株式会社 オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法
US5856481A (en) 1994-07-28 1999-01-05 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
IL139728A (en) 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
WO1997030167A1 (en) 1996-02-13 1997-08-21 The Trustees Of The University Of Pennsylvania Method of treating liver disorders
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US6258849B1 (en) 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
CA2374273A1 (en) 1999-05-21 2000-11-30 Takeda Chemical Industries, Ltd. Liver function controlling agents
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
JP3211824B1 (ja) 2000-10-26 2001-09-25 味の素株式会社 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法
TWI309162B (en) 2001-03-15 2009-05-01 Rikagaku Kenkyusho Amino acid composition for improving functional disorder of liver
US6503530B1 (en) 2001-11-01 2003-01-07 Chunghee Kimberly Kang Method of preventing development of severe metabolic derangement in inborn errors of metabolism
US20030105104A1 (en) * 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
CN1383815A (zh) 2002-05-08 2002-12-11 刘万忠 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法
US20040152784A1 (en) 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
AU2003261825A1 (en) 2002-08-30 2004-03-19 Ajinomoto Co., Inc. Therapeutic agent for hepatic disease
US20050059150A1 (en) 2003-09-17 2005-03-17 Becton, Dickinson And Company Environments that maintain function of primary liver cells
MXPA03009902A (es) 2003-10-29 2005-05-03 Manuel Francisco Lara Och Jose Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio.
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
JP4954867B2 (ja) 2004-05-06 2012-06-20 オステオロジックス エイ／エス 有機金属塩類を製造するための高収率で迅速な合成法
WO2006059237A1 (en) 2004-08-30 2006-06-08 Lunamed, Inc. 4-phenylbutyric acid controlled-release formulations for therapeutic use
JP5116479B2 (ja) 2004-11-26 2013-01-09 ユーシーエル ビジネス ピーエルシー オルニチンならびにフェニルアセテートまたはフェニルブチレートを含む、肝性脳症を治療するための組成物
GB0426141D0 (en) 2004-11-26 2004-12-29 Ucl Biomedica Plc Treatment
JP5221858B2 (ja) 2006-08-30 2013-06-26 株式会社日立ハイテクノロジーズ 欠陥検査装置、及び欠陥検査方法
AU2015221466B2 (en) 2009-04-03 2017-02-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
ES2928586T3 (es) 2009-04-03 2022-11-21 Ocera Therapeutics Inc Fenilacetato de L-ornitina y métodos para elaborar el mismo
CA2763894A1 (en) 2009-06-02 2011-01-13 Salix Pharmaceuticals, Ltd. Use of rifaximin to maintain remission of hepatic encephalopathy
KR101715008B1 (ko) 2009-06-08 2017-03-22 유씨엘 비즈니스 피엘씨 Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복
AU2014250643B2 (en) 2009-06-08 2016-07-14 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
JP6087284B2 (ja) 2010-10-06 2017-03-01 オセラ セラピューティクス， インコーポレイテッド Ｌ−オルニチンフェニルアセテートを製造するための方法
RU2755904C2 (ru) 2015-04-20 2021-09-22 Осера Терапьютикс, Инк. Составы l-орнитин фенилацетата
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate

Also Published As

Publication number Publication date
US20170189364A1 (en) 2017-07-06
SI2153870T1 (sl) 2014-05-30
JP5116479B2 (ja) 2013-01-09
ATE457187T1 (de) 2010-02-15
JP2008521784A (ja) 2008-06-26
CA2589261C (en) 2014-07-08
PL2319581T3 (pl) 2015-10-30
DK2153870T3 (en) 2014-03-10
JP2012246294A (ja) 2012-12-13
CY1112259T1 (el) 2015-12-09
CA2589261A1 (en) 2006-06-01
KR101380446B1 (ko) 2014-04-01
CN102512408B (zh) 2015-11-25
EP1824563B1 (en) 2010-02-10
EA200900105A1 (ru) 2009-08-28
ES2448549T3 (es) 2014-03-14
US20120259016A1 (en) 2012-10-11
EA018007B1 (ru) 2013-04-30
EP2319581A1 (en) 2011-05-11
WO2006056794A1 (en) 2006-06-01
CN102512408A (zh) 2012-06-27
MX2007006171A (es) 2007-10-08
AU2005308622A1 (en) 2006-06-01
EP1824563A1 (en) 2007-08-29
NO342198B1 (no) 2018-04-16
US10610506B2 (en) 2020-04-07
DE602005019319D1 (de) 2010-03-25
PL1824563T3 (pl) 2010-07-30
PT1824563E (pt) 2010-05-17
SI2319581T1 (sl) 2015-10-30
DK2319581T3 (en) 2015-06-01
PT2319581E (pt) 2015-06-30
NO20073254L (no) 2007-08-23
IL183401A0 (en) 2007-10-31
CY1114979T1 (el) 2016-12-14
NO341491B1 (no) 2017-11-27
PL2153870T3 (pl) 2014-05-30
AU2005308622B2 (en) 2012-08-02
SG158073A1 (en) 2010-01-29
US9566257B2 (en) 2017-02-14
JP5612030B2 (ja) 2014-10-22
CY1116314T1 (el) 2017-02-08
ES2341120T3 (es) 2010-06-15
EA200701146A1 (ru) 2008-02-28
EP2319581B1 (en) 2015-02-25
DK1824563T3 (da) 2010-05-31
EP2153870B1 (en) 2013-12-25
US8389576B2 (en) 2013-03-05
ES2537974T3 (es) 2015-06-16
SI1824563T1 (sl) 2010-07-30
KR20070100721A (ko) 2007-10-11
NO20161808A1 (no) 2016-11-16
EA011716B1 (ru) 2009-04-28
HK1141471A1 (en) 2010-11-12
US20080119554A1 (en) 2008-05-22
PT2153870E (pt) 2014-03-12
EP2153870A1 (en) 2010-02-17
NZ555870A (en) 2009-09-25

Similar Documents

Publication Publication Date Title
IL183401A (en) Use of ornithine and ornithine with at least one of phenylacetate and phenylbutyrate in the manufacture of products and compositions containing them for use in preventing or treating liver decompensation or hepatic encephalopathy
ATE376828T1 (de) Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms
DE502007002101D1 (de) Arzneimittel mit Dobesilat-Calcium zur Behandlung und Prophylaxe von Sehnenerkrankungen
DE60135647D1 (de) Zusammensetzungen zur normalisierung des zirkadianen rythmus
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
BR0313747A (pt) Inibidores de transcriptase reversa de não-nucleosìdeo
WO2007109172A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
EP1543830A4 (en) ANTISEPTIC BACTERICIDES, AND COSMETICS, MEDICAMENTS AND FOODS CONTAINING ANTISEPTIC BACTERICIDES
WO2007109154A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109160A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109182A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
EP1767212A4 (en) USE OF A PLANT OF THE GENUS AMPELOPSIS AND EXTRACTS OF THIS PLANT FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A FUNCTIONAL FOOD
WO2007028022A3 (en) Novel compounds as p2x7 modulators and uses thereof
SE0301885D0 (sv) New use IV
TNSN07283A1 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
ATE410154T1 (de) Pharmazeutische zusammensetzung enthaltend 2,4- dichlorbenzylalkohol und amylmetakresol
ATE293983T1 (de) Verwendung von n-acetyl-d-glucosamin bei der herstellung eines arzneimittels zur unterdrückung der nebenwirkungen von strahlentherapie und chemotherapie
JO2666B1 (en) Use of agomelatine for medications to treat bilateral mental disorders
ATE546137T1 (de) Pharmazeutische zusammensetzungen zur behandlung von warzen
UA98446C2 (ru) 1-ФЕНИЛ-4-о-ТОЛИЛАМИНО-1,5-ДИГИДРОПИРОЛ-2-ОН, ПРОЯВЛЯЮЩИЙ АНАЛЬГЕТИЧЕСКУЮ И ПРОТИВОВОСПАЛИТЕЛЬНУЮ АКТИВНОСТЬ
HK1136967A1 (zh) 作为p2x7调节剂的双环杂芳基化合物及其用途
BR0300734A (pt) Processo de obtenção de extrato potencializado de maytenus spp, fração ou extrato, composição, unidade de dosagem, método para previnir, inibir ou suspender processo ulcerativo, método de tratamento de processo ulcerativo e uso

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed